Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.73 |
| ▸ | NPC1 | O15118 | 3/20 | 0.61 |
| ▸ | RAB9A | P51151 | 3/20 | 0.61 |
| ▸ | POLB | P06746 | 3/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.59 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.59 |
| ▸ | MEN1 | O00255 | 1/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.59 |
| ▸ | GAA | P10253 | 1/20 | 0.59 |
| ▸ | HPGD | P15428 | 3/20 | 0.58 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.58 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.58 |
| ▸ | LMNA | P02545 | 1/20 | 0.58 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.56 |
| ▸ | CA2 | P00918 | 1/20 | 0.56 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL27694741 | 0.98 | SMN1; SMN2 (0.71) | SMN1; SMN2NPC1RAB9APOLBALDH1A1 | |
| Acetic Acid SCHEMBL6261851 | 0.92 | SMN1; SMN2 (0.63) | SMN1; SMN2NPC1RAB9APOLBALDH1A1 | |
| Acetic Acid SCHEMBL6262675 | 0.92 | SMN1; SMN2 (0.63) | SMN1; SMN2NPC1RAB9APOLBALDH1A1 | |
| SCHEMBL31558918 | 0.86 | SMN1; SMN2 (0.80) | SMN1; SMN2NPC1RAB9APOLBALDH1A1 | |
| SCHEMBL7977040 | 0.85 | SMN1; SMN2 (0.73) | SMN1; SMN2NPC1RAB9APOLBALDH1A1 | |
| SCHEMBL29460273 | 0.85 | SMN1; SMN2 (0.79) | SMN1; SMN2NPC1RAB9APOLBALDH1A1 | |
| SCHEMBL18415475 | 0.85 | SMN1; SMN2 (1.00) | SMN1; SMN2NPC1RAB9APOLBALDH1A1 | |
| SCHEMBL21065524 | 0.85 | SMN1; SMN2 (0.79) | SMN1; SMN2NPC1RAB9APOLBALDH1A1 | |
| SCHEMBL30522589 | 0.85 | SMN1; SMN2 (1.00) | SMN1; SMN2NPC1RAB9APOLBALDH1A1 | |
| SCHEMBL11096788 | 0.84 | SMN1; SMN2 (0.61) | SMN1; SMN2NPC1RAB9APOLBALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 58 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260028333-A1 | NEW COMPOUNDS | VICORE PHARMA AB (SE) | 2026-01-29 | — | — | US | claimed |
| US-20220388994-A1 | NEW COMPOUNDS | VICORE PHARMA AB (SE) | 2022-12-08 | — | — | US | claimed |
| CN-115109049-A | Triazine compound containing aryl urea structure and application thereof | 江西科技师范大学 | 2022-09-27 | — | — | CN | claimed |
| EP-4031240-A1 | NEW COMPOUNDS | Vicore Pharma AB (SE) | 2022-07-27 | — | — | EP | claimed |
| CN-114786774-A | Novel compounds | 维科尔药物公司 | 2022-07-22 | — | — | CN | claimed |
| US-20160369208-A1 | UREA GELLANT | THE PROCTER & GAMBLE COMPANY | 2016-12-22 | — | — | US | claimed |
| CN-101981047-A | Novel lupane derivatives | VIROCHEM PHARMA INC | 2011-02-23 | — | — | CN | claimed |
| EP-1725238-A4 | M 3 MUSCARINIC ACETYLCHOLINE RECEPTOR ANTAGONISTS | GLAXO GROUP LTD (GB) | 2009-04-01 | — | — | EP | claimed |
| EP-1725238-A2 | M 3 MUSCARINIC ACETYLCHOLINE RECEPTOR ANTAGONISTS | GLAXO GROUP LIMITED (GB) | 2006-11-29 | — | — | EP | claimed |
| WO-2005094251-A2 | M3MUSCARINIC ACETYLCHOLINE RECEPTOR ANTAGONISTS | GLAXO GROUP LIMITED (GB) | 2005-10-13 | — | — | WO | claimed |
| US-5096978-A | Butadiene polymers having improved scorch delay and fast cure rates; tires; treads | MONSANTO COMPANY (US) | 1992-03-17 | — | — | US | claimed |
| EP-0364428-A1 | Vulcanizable synthetic rubber compositions cure-activated by substituted ureas | Monsanto Company (US) | 1990-04-18 | — | — | EP | claimed |
| EP-4746880-A2 | METHODS OF TREATING DILATED CARDIOMYOPATHY | Regencor, Inc. (US) | 2026-05-27 | — | — | EP | disclosed |
| US-20260028333-A1 | NEW COMPOUNDS | VICORE PHARMA AB (SE) | 2026-01-29 | — | — | US | disclosed |
| US-20250304576-A1 | IKK INHIBITORS | CANCER RESEARCH TECH LTD (GB) | 2025-10-02 | — | — | US | disclosed |
| WO-2025024320-A2 | METHODS OF TREATING DILATED CARDIOMYOPATHY | REGENCOR, INC. (US) | 2025-01-30 | — | — | WO | disclosed |
| EP-0934296-A1 | CHROMAN DERIVATIVES | NISSAN CHEMICAL INDUSTRIES, LIMITED (JP) | 1999-08-11 | — | — | EP | disclosed |
| WO-1998004542-A1 | CHROMAN DERIVATIVES | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 1998-02-05 | — | — | WO | disclosed |
| US-5096978-A | Butadiene polymers having improved scorch delay and fast cure rates; tires; treads | MONSANTO COMPANY (US) | 1992-03-17 | — | — | US | disclosed |
| EP-0364428-A1 | Vulcanizable synthetic rubber compositions cure-activated by substituted ureas | Monsanto Company (US) | 1990-04-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260028333-A1 | NEW COMPOUNDS | AGTR1, AGTR2, REN | SMN1; SMN2 4062/4885NPC1 897/4885RAB9A 1808/4885 |
| US-20220388994-A1 | NEW COMPOUNDS | RXFP3, RXFP4, RXFP1 | SMN1; SMN2 4226/4885NPC1 2981/4885RAB9A 982/4885 |
| US-20250304576-A1 | IKK INHIBITORS | NFKBIA, IKBKE, IKBKB | SMN1; SMN2 3836/4885NPC1 1965/4885RAB9A 2770/4885 |
| US-20160369208-A1 | UREA GELLANT | UGP2, UGGT1, SLC14A1 | SMN1; SMN2 4419/4885NPC1 1374/4885RAB9A 2575/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.